Who
Michael Severino
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Sarepta Therapeutics; Director, Avantor; Director, Viatris; Vice Chairman, AbbVie.
In numbers
- Trades disclosed
- 116
- Buys
- 0
- Sells
- 10
- Bought
- $0
- Sold
- $104.3M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 2 Jun 2014
- Last trade
- 28 Jul 2026
- Last filed
- 29 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Jul 2026filed 29 Jul 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code A | —756,104 | filing |
| 28 Jul 2026filed 29 Jul 2026 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,224,342 at $0.00 | filing |
| 28 Jul 2026filed 29 Jul 2026 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,224,342 at $0.00 | filing |
| 28 Jul 2026filed 29 Jul 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code A | —756,104 | filing |
| 7 May 2026filed 11 May 2026 | AVTR AvantorLife-science tools | SEC FORM 4 Code A | —25,270 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | AVTR AvantorLife-science tools | SEC FORM 4 Code A | —25,270 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —25,112 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —919 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —25,112 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —25,112 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —918.46 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —15,890 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —918.455 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —15,890 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —25,112 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | VTRS ViatrisPharmaceuticals | SEC FORM 4 Code M | —919 at $0.00 | filing |
| 12 May 2025filed 13 May 2025 | VTRS Viatrisoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —25,112 at $0.00 | filing |
| 8 May 2025filed 12 May 2025 | AVTR AvantorLife-science tools | SEC FORM 4 Code A | —17,100 at $0.00 | filing |
| 9 May 2024filed 13 May 2024 | AVTR AvantorLife-science tools | SEC FORM 4 Code A | —8,477 at $0.00 | filing |
| 11 May 2023filed 15 May 2023 | AVTR AvantorLife-science tools | SEC FORM 4 Code A | —9,808 at $0.00 | filing |
News
AbbVie vs. Bristol Myers: Is AbbVie's Valuation Premium Worth Paying?ABBV · insidermonkey.com · 19 Oct 2026AbbVie: SKYRIZI (risankizumab) and RINVOQ (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026ABBV · finanznachrichten.de · 17 Oct 2026Pfizer vs. AbbVie: Is the Cheaper Pharma Stock Really the Better Investment?ABBV · insidermonkey.com · 16 Oct 2026
0 headlines in the last 90 days name Michael Severino; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.